Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 3.54
KYTH's Cash to Debt is ranked higher than
76% of the 1152 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. KYTH: 3.54 )
KYTH' s 10-Year Cash to Debt Range
Min: 3.54   Max: No Debt
Current: 3.54

F-Score: 1
Z-Score: 8.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -134.32
KYTH's ROE (%) is ranked lower than
56% of the 1129 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.93 vs. KYTH: -134.32 )
KYTH' s 10-Year ROE (%) Range
Min: -129.61   Max: -47.46
Current: -134.32

-129.61
-47.46
ROA (%) -97.86
KYTH's ROA (%) is ranked lower than
57% of the 1161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. KYTH: -97.86 )
KYTH' s 10-Year ROA (%) Range
Min: -97.98   Max: -38.51
Current: -97.86

-97.98
-38.51
ROC (Joel Greenblatt) (%) -13846.45
KYTH's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.14 vs. KYTH: -13846.45 )
KYTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -27136.04   Max: -3013.33
Current: -13846.45

-27136.04
-3013.33
» KYTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

KYTH Guru Trades in Q1 2014

Jim Simons 116,400 sh (+182.52%)
RS Investment Management 288,700 sh (+18.66%)
» More
Q2 2014

KYTH Guru Trades in Q2 2014

Steven Cohen 15,200 sh (unchged)
Jim Simons Sold Out
RS Investment Management 283,181 sh (-1.91%)
» More
Q3 2014

KYTH Guru Trades in Q3 2014

RS Investment Management 289,881 sh (+2.37%)
Steven Cohen Sold Out
» More
Q4 2014

KYTH Guru Trades in Q4 2014

RS Investment Management 359,371 sh (+23.97%)
» More
» Details

Insider Trades

Latest Guru Trades with KYTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.00
KYTH's P/B is ranked lower than
60% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. KYTH: 19.00 )
KYTH' s 10-Year P/B Range
Min: 6.69   Max: 19.4
Current: 19

6.69
19.4
Current Ratio 4.90
KYTH's Current Ratio is ranked higher than
87% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. KYTH: 4.90 )
KYTH' s 10-Year Current Ratio Range
Min: 2.71   Max: 9.86
Current: 4.9

2.71
9.86
Quick Ratio 4.90
KYTH's Quick Ratio is ranked higher than
89% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. KYTH: 4.90 )
KYTH' s 10-Year Quick Ratio Range
Min: 2.71   Max: 9.86
Current: 4.9

2.71
9.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.60
KYTH's Price/Net Cash is ranked higher than
87% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. KYTH: 20.60 )
KYTH' s 10-Year Price/Net Cash Range
Min: 5.66   Max: 14.16
Current: 20.6

5.66
14.16
Price/Net Current Asset Value 20.60
KYTH's Price/Net Current Asset Value is ranked higher than
79% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. KYTH: 20.60 )
KYTH' s 10-Year Price/Net Current Asset Value Range
Min: 5.43   Max: 13.76
Current: 20.6

5.43
13.76
Price/Tangible Book 19.30
KYTH's Price/Tangible Book is ranked lower than
54% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. KYTH: 19.30 )
KYTH' s 10-Year Price/Tangible Book Range
Min: 5.42   Max: 23.14
Current: 19.3

5.42
23.14
Earnings Yield (Greenblatt) -12.20
KYTH's Earnings Yield (Greenblatt) is ranked lower than
57% of the 1148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. KYTH: -12.20 )
KYTH' s 10-Year Earnings Yield (Greenblatt) Range
Min: -17.4   Max: 0
Current: -12.2

-17.4
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:KYT.Germany,
KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.
» More Articles for KYTH

Headlines

Articles On GuruFocus.com
My Portfolio Mar 08 2015 

More From Other Websites
Are Billions About to Be Made in Cosmetic Dermatology by 3 Companies? Apr 17 2015
Street Talk: GM, SLB, M, GRMN & KYTH Apr 10 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program Apr 06 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program Apr 06 2015
KYTHERA Biopharmaceuticals Inc Corporate Call - Outlook investor scheduled for 4:30 pm ET today Mar 26 2015
KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program Mar 20 2015
KYTHERA Biopharmaceuticals Announces 2014 Operating Results Mar 20 2015
KYTHERA Biopharmaceuticals Announces 2015 Outlook Call Mar 20 2015
KYTHERA Biopharmaceuticals Announces FDA Advisory Committee Unanimously (17-0) Recommends to Approve... Mar 20 2015
KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common Stock Mar 20 2015
KYTHERA Biopharmaceuticals Announces Proposed Public Offering of Common Stock Mar 20 2015
KYTHERA Biopharmaceuticals Announces 2015 Outlook Call Mar 19 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 16 2015
KYTHERA Biopharmaceuticals Announces Closing of Public Offering and Exercise of Underwriters'... Mar 16 2015
KYTHERA Biopharmaceuticals Announces Pricing of Public Offering of Common Stock Mar 10 2015
Kythera's Double Chin Drug Backed by FDA Advisory Committee - Analyst Blog Mar 10 2015
FDA Panel Backs Kythera Double-Chin Treatment Mar 09 2015
It was a strong start to the week for equities... Mar 09 2015
KYTHERA Biopharmaceuticals Announces Proposed Public Offering of Common Stock Mar 09 2015
KYTHERA Biopharmaceuticals Announces FDA Advisory Committee Unanimously (17-0) Recommends to Approve... Mar 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK